KR20190036272A - Composition comprising culture or its extract of lactobacillus crustorum - Google Patents
Composition comprising culture or its extract of lactobacillus crustorum Download PDFInfo
- Publication number
- KR20190036272A KR20190036272A KR1020170125293A KR20170125293A KR20190036272A KR 20190036272 A KR20190036272 A KR 20190036272A KR 1020170125293 A KR1020170125293 A KR 1020170125293A KR 20170125293 A KR20170125293 A KR 20170125293A KR 20190036272 A KR20190036272 A KR 20190036272A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- strain
- composition
- culture
- lactobacillus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 241000861211 Lactobacillus crustorum Species 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims abstract description 24
- 230000008591 skin barrier function Effects 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 10
- 239000006166 lysate Substances 0.000 claims abstract description 10
- 230000036560 skin regeneration Effects 0.000 claims abstract description 10
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 8
- 230000036548 skin texture Effects 0.000 claims abstract description 7
- 230000037394 skin elasticity Effects 0.000 claims abstract description 6
- 229940106189 ceramide Drugs 0.000 claims description 24
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 22
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 22
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 22
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 210000002510 keratinocyte Anatomy 0.000 description 14
- -1 sphingoid lipid Chemical class 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 210000004927 skin cell Anatomy 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 2
- 229940033329 phytosphingosine Drugs 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
본 명세서에는 락토바실러스 크러스토룸 균주, 이의 파쇄물, 이의 배양물, 또는 상기 균주, 파쇄물 또는 배양물의 추출물을 포함하는 조성물이 개시된다.Disclosed herein is a composition comprising a Lactobacillus crustarium strain, a lysate thereof, a culture thereof, or an extract of said strain, lysate or culture.
인체 피부의 표면은 기저층으로부터 분화되어 성숙된 각질형성세포가 퇴화된 각질세포로 이루어져 있다. 이들 각질세포는 각질층에 다량 존재하는 세라마이드의 이중사슬 라멜라 구조에 의해 결합되어 있어 매끄럽고 탄력있는 피부를 유지하게 한다. The surface of the human skin consists of keratinocytes in which the mature keratinocytes are differentiated from the basal layer and degenerated. These keratinocytes are bound by the ceramide double-stranded lamellar structure, which is present in the stratum corneum, to maintain a smooth and resilient skin.
세라마이드는 스핑고신 (Sphingosine) 또는 파이토스핑고신 (Phytosphingosine)에 지방산이 연결되어 있는 구조를 갖는 스핑고 지질의 일종으로서, 피부 각질층을 구성하는 각질세포 간의 지질 중 약 40% 이상을 차지하고, 각질층의 구조 형성이나 기능을 나타내는데 필수적인 성분으로 작용하여 각질층이 견고함과 유연성을 가지게 한다. Ceramide is a type of sphingoid lipid with a fatty acid linked to Sphingosine or Phytosphingosine. It occupies more than 40% of the lipid between keratinocytes constituting the skin stratum corneum. It acts as an essential ingredient to demonstrate its function, giving the stratum corneum firmness and flexibility.
이러한 세라마이드는 피부 장벽 유지, 수분의 증발을 억제하는 지질 장벽의 역할 및 항상성 (homeostasis)에 기여하게 되며, 외부의 물리적, 화학적 손상에 대해 빠른 복원력을 제공하게 된다. 따라서, 세라마이드가 부족하면 피부가 건조, 손상되며 탄력을 잃고 피부가 거칠어진다. 또한, 세라마이드는 피부 표면에서 파이토스핑고신으로 분해됨으로써 외부 유해 미생물에 대한 항균 장벽으로 작용하며 염증의 조절과 상처 회복에도 중요한 기능을 수행한다. 최근에는 세라마이드 관련 대사산물 (metabolite)이 세포대사를 조절하는 신호전달자로서의 역할이 알려지면서 피부 생리 조절을 목적으로 하는 연구가 다양하게 이루어지고 있고, 피부 각질층의 주요 성분으로서의 특성 이외에도 여러 가지 생리학적 기능이 보고되고 있다.These ceramides contribute to the maintenance of skin barrier, the role of lipid barriers to inhibit water evaporation and homeostasis, and provide a quick resilience to external physical and chemical damage. Therefore, when the ceramide is insufficient, the skin becomes dry, damaged, loses its elasticity, and the skin becomes rough. Ceramide also breaks down from the skin surface to phytosphingosine, which acts as an antimicrobial barrier against harmful microorganisms. It also plays an important role in the control of inflammation and wound healing. Recently, metabolism of ceramide related metabolism has been known to act as a signal transducer to regulate cell metabolism. There have been various studies for the purpose of regulating skin physiology. In addition to its properties as a main component of the skin horny layer, various physiological functions Is being reported.
한편, 피부 재생은 손상에 대한 조직의 반응이며 조직 회복의 과정으로, 주화성 (chemotaxis), 세포의 분화 및 복제 (differentiation and replication), 기질 단백질 (matrix protein)의 합성, 혈관의 신생 및 창상의 재구성 등을 포함하는 생물학적 과정이다 (Steed, D.L. et al., Clin. Plast. Surg., 25:397(1998)). 피부가 손상되면 표피 (epidermis)에서는 기저세포 (basal layer cell)의 증식이 활발하게 일어난다.On the other hand, skin regeneration is a tissue response to injury, and as a process of tissue regeneration, chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, (Steed, DL et al., Clin. Plast. Surg., 25: 397 (1998)). When the skin is damaged, basal layer cells proliferate actively in the epidermis.
락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주는 빵 반죽에 사용되는 발효물인 사워 도우(sourdough)에서 발견되는 균주로서 섭취 시의 그 효능 또는 피부 개선 효과 등에 관해 알려진 바가 없다. Lactobacillus crustorum strain is a strain found in sourdough which is a fermentation product used for bread dough, and its effect on ingestion or skin improving effect is not known.
일 측면에서, 본 명세서는 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주의 새로운 용도를 제공하는 것을 목적으로 한다.In one aspect, the present disclosure aims to provide a new use of Lactobacillus crustorum strains.
다른 측면에서, 본 명세서는 피부 상태 개선 효과를 갖는 락토바실러스 크러스토룸 (Lactobacillus crustorum) JTA 균주를 제공하는 것을 목적으로 한다.In another aspect, the present invention aims to provide a Lactobacillus crustorum JTA strain having skin condition improving effect.
일 측면에서, 본 명세서에 개시된 기술은 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주; 이의 파쇄물; 이의 배양물; 또는 상기 균주, 파쇄물 또는 배양물의 추출물을 유효성분으로 포함하는 피부 상태 개선용 조성물을 제공한다.In one aspect, the techniques disclosed herein include Lactobacillus crustorum strain; Disruption thereof; A culture thereof; Or an extract of said strain, lysate or culture as an active ingredient.
예시적인 일 구현예에서, 상기 균주는 기탁번호가 KCCM12048P인 락토바실러스 크러스토룸 JTA일 수 있다.In one exemplary embodiment, the strain may be Lactobacillus crestorum JTA with accession number KCCM 12048P.
예시적인 일 구현예에서, 상기 균주는 서열번호 1의 염기서열을 포함하는 16S rDNA를 갖는 것일 수 있다.In an exemplary embodiment, the strain may be one having 16S rDNA comprising the nucleotide sequence of SEQ ID NO: 1.
예시적인 일 구현예에서, 상기 추출물은 열수 추출물일 수 있다.In one exemplary embodiment, the extract may be a hot-water extract.
예시적인 일 구현예에서, 상기 유효성분은 조성물 전체 중량을 기준으로 0.001 내지 30 중량%로 포함되는 것일 수 있다.In an exemplary embodiment, the active ingredient may be included in an amount of 0.001 to 30% by weight based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 피부 재생 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may be one having a skin regeneration use.
예시적인 일 구현예에서, 상기 조성물은 피부결 개선 용도를 갖는 것일 수 있다.In one exemplary embodiment, the composition may be one having a skin tone improving application.
예시적인 일 구현예에서, 상기 조성물은 피부 보습 용도를 갖는 것일 수 있다.In one exemplary embodiment, the composition may be one having a skin moisturizing application.
예시적인 일 구현예에서, 상기 조성물은 피부 탄력 강화 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may be one having a skin elasticity-enhancing use.
예시적인 일 구현예에서, 상기 조성물은 피부 장벽 강화 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may be one having a skin barrier intensifying application.
예시적인 일 구현예에서, 상기 조성물은 세라마이드 합성 촉진 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may be one having ceramide synthesis promoting use.
다른 측면에서, 본 명세서에 개시된 기술은 기탁번호가 KCCM12048P인 락토바실러스 크러스토룸 (Lactobacillus crustorum) JTA 균주를 제공한다.In another aspect, the technology disclosed herein provides a Lactobacillus crustorum JTA strain, wherein the deposit number is KCCM 12048P.
예시적인 일 구현예에서, 상기 균주는 세라마이드 합성 촉진 기능을 가지는 것일 수 있다.In an exemplary embodiment, the strain may have a ceramide synthesis promoting function.
예시적인 일 구현예에서, 상기 균주는 피부 재생, 피부결 개선, 피부 보습, 피부 탄력 강화 및 피부 장벽 강화로 이루어진 군에서 선택되는 1 이상의 피부 상태 개선 기능을 가지는 것일 수 있다.In an exemplary embodiment, the strain may be one having at least one skin condition improvement function selected from the group consisting of skin regeneration, skin texture improvement, skin moisturization, skin elasticity enhancement, and skin barrier enhancement.
일 측면에서, 본 명세서에 개시된 기술은 피부 상태 개선을 위한 친환경 소재의 원료를 제공하는 효과가 있다.In one aspect, the techniques disclosed herein have the effect of providing a source of environmentally friendly materials for skin condition improvement.
다른 측면에서, 본 명세서에 개시된 기술은 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주의 피부 상태 개선 용도를 제공하는 효과가 있다. 상기 균주는 피부 재생, 피부결 개선, 피부 보습, 피부 탄력 강화 및 피부 장벽 강화 효과를 제공한다.In another aspect, the techniques disclosed herein have the effect of providing a skin condition improving application of a Lactobacillus crustorum strain. The strain provides skin regeneration, skin texture improvement, skin moisturization, skin elasticity enhancement and skin barrier enhancement.
다른 측면에서, 본 명세서에 개시된 기술은 피부 상태 개선 용도를 갖는 락토바실러스 크러스토룸 (Lactobacillus crustorum) JTA 균주를 제공하는 효과가 있다.In another aspect, the technique disclosed herein is effective to provide a Lactobacillus crustorum JTA strain having a skin condition improving use.
도 1은 본 명세서에 따른 기탁번호가 KCCM12048P인 락토바실러스 크러스토룸 (Lactobacillus crustorum) JTA 균주의 16s rDNA 시퀀스 (서열번호 1)를 나타낸 것이다.
도 2는 본 명세서의 일 실시예에 따른 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주의 피부 세포 생장 촉진 효과를 나타낸 것이다 (* : P<0.05).
도 3은 본 명세서의 일 실시예에 따른 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주의 세라마이드 생성효소 활성 촉진 효과를 나타낸 것이다 (* : P<0.05).
도 4는 본 명세서의 일 실시예에 따른 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주의 세라마이드 생성 증진 효과를 나타낸 것이다 (* : P<0.05).Figure 1 shows the 16s rDNA sequence (SEQ ID NO: 1) of the Lactobacillus crustorum JTA strain with the accession number KCCM12048P according to the present specification.
FIG. 2 shows the effect of promoting skin cell growth of a Lactobacillus crustorum strain according to an embodiment of the present invention (*: P <0.05 ).
FIG. 3 shows the effect of promoting ceramide-producing enzyme activity of Lactobacillus crustorum strain according to one embodiment of the present invention (*: P <0.05 ).
FIG. 4 shows the effect of enhancing ceramide production of Lactobacillus crustorum strain according to one embodiment of the present invention (*: P <0.05 ).
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
일 측면에서, 본 명세서에 개시된 기술은 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주; 이의 파쇄물; 이의 배양물; 또는 상기 균주, 파쇄물 또는 배양물의 추출물을 유효성분으로 포함하는 피부 상태 개선용 조성물을 제공한다.In one aspect, the techniques disclosed herein include Lactobacillus crustorum strain; Disruption thereof; A culture thereof; Or an extract of said strain, lysate or culture as an active ingredient.
다른 측면에서, 본 명세서에 개시된 기술은 기탁번호가 KCCM12048P인 락토바실러스 크러스토룸 (Lactobacillus crustorum) JTA 균주를 제공한다.In another aspect, the technology disclosed herein provides a Lactobacillus crustorum JTA strain, wherein the deposit number is KCCM 12048P.
본 명세서에서 "유효성분"은 단독으로 목적으로 하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체 등과 함께 목적으로 하는 활성을 나타낼 수 있는 성분을 의미한다.As used herein, the term " active ingredient " refers to a component that can exhibit the desired activity alone, such as a carrier that exhibits the desired activity alone or is itself inactive.
미생물 자원은 석유, 물 등과 달리 재생산할 수 있다는 점에서 지속 가능한 자원으로 활용할 수 있는 이점이 있다.Microbial resources are advantageous as sustainable resources in that they can be reproduced unlike petroleum and water.
예시적인 일 구현예에서, 상기 균주는 균주를 배양하여 배양액을 원심분리한 다음, 멸균된 생리식염수로 세척한 후 용매, 예컨대 멸균유에 분산시키고 동결건조하여 동결건조분말 형태로 제조하여 사용될 수 있다.In an exemplary embodiment, the strain may be used by preparing a lyophilized powder form by culturing a strain, centrifuging the culture, washing with sterile physiological saline, dispersing the same in a solvent such as sterilized oil, and lyophilizing.
상기 균주의 파쇄물이란, 균주 자체를 화학적 또는 물리적 힘에 의하여 파쇄하여 얻은 산물을 의미할 수 있다.The lysate of the strain may mean a product obtained by breaking the strain itself by chemical or physical force.
상기 균주의 배양물이란, 배양물의 형태를 불문하고 균주를 배양한 배지 내에 포함되어 있는 일부 또는 모든 물질을 포함하는 물질을 의미할 수 있으며, 예컨대 균주 배양의 결과물인 대사물 또는 분비물을 포함하는 물질 또는 그 파쇄물을 의미할 수 있고, 균주 자체도 배양물 내에 포함되어 있을 수 있다. 또한, 상기 배양물은 발효물을 포함하는 것을 의미할 수 있다.The culture of the strain may refer to a substance including some or all of the substances contained in the medium in which the strain has been cultured regardless of the form of the culture. For example, a substance containing metabolites or secretions resulting from the culture of the strain Or the lysate thereof, and the strain itself may be contained in the culture. In addition, the culture may mean that it contains a fermented product.
상기 추출물이란, 균주 자체, 균주의 파쇄물, 균주의 배양물 또는 이들의 혼합물을 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고 추출하여 얻어진 산물을 의미할 수 있으며, 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함하는 광범위한 개념이다.The extract may be a product obtained by extracting the strain itself, a lysate of the strain, a culture of the strain, or a mixture thereof, regardless of the extraction method, the extraction solvent, the extracted component or the form of the extract, Or a material that can be obtained by processing or treating the same.
예시적인 일 구현예에서, 상기 추출물은 가열 추출물일 수 있다.In one exemplary embodiment, the extract may be a heated extract.
예시적인 일 구현예에서, 상기 추출물은 50 ℃ 이상, 60 ℃ 이상, 70 ℃ 이상, 80 ℃ 이상, 90 ℃ 이상 또는 100 ℃ 이하의 온도에서 추출한 것일 수 있다. In one illustrative embodiment, the extract may be extracted at a temperature of greater than or equal to 50 ° C, greater than or equal to 60 ° C, greater than or equal to 70 ° C, greater than or equal to 80 ° C, greater than or equal to 90 ° C, or less than or equal to 100 ° C.
예시적인 일 구현예에서, 상기 추출물은 열수 추출물일 수 있다.In one exemplary embodiment, the extract may be a hot-water extract.
예시적인 일 구현예에서, 상기 유효성분은 조성물 전체 중량을 기준으로 0.001 내지 30 중량%로 포함되는 것일 수 있다. 다른 측면에서, 상기 유효성분은 조성물 전체 중량을 기준으로 0.001 중량% 이상, 0.01 중량% 이상, 0.1 중량% 이상, 0.5 중량% 이상, 1 중량% 이상, 1.5 중량% 이상 또는 2 중량% 이상이면서 30 중량% 이하, 25 중량% 이하, 20 중량% 이하, 15 중량% 이하, 10 중량% 이하 또는 5 중량% 이하로 포함되는 것일 수 있다.In an exemplary embodiment, the active ingredient may be included in an amount of 0.001 to 30% by weight based on the total weight of the composition. In another aspect, the active ingredient is present in an amount of at least 0.001%, at least 0.01%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, or at least 2% 25 wt% or less, 20 wt% or less, 15 wt% or less, 10 wt% or less, or 5 wt% or less.
피부는 표피층, 진피층, 피하지방층, 근육층으로 이루어져 있으며, 표피층의 각질층은 그 자체가 단백질과 지질의 2중 구조물로 되어 있는 세포막 형태로서, 각질층은 여러 가지 외적 요인과 내적 요인에 의해 피부의 활성이 감소하거나 보호 장벽에 틈이 생기면서 단백질-지질의 2중 구조가 점점 친수성과 친유성의 양친매성을 잃고 탈락하게 되어 피부 장벽이 손상하게 된다. 한편, 각질형성세포는 천연보습인자와 세라마이드와 같은 세포간 지방질을 생성하면서 각질층을 형성함으로써 각질층이 견고함과 유연성의 탄력 및 보습을 갖고 강화된 피부 장벽으로서의 기능을 수행할 수 있도록 한다. Skin is composed of epidermal layer, dermal layer, subcutaneous fat layer and muscle layer. The stratum corneum of skin layer itself is a membrane structure composed of protein and lipid double structure. The stratum corneum is affected by various external factors and internal factors. Or a gap in the protective barrier, the protein-lipid bilayer structure gradually loses its hydrophilic and lipophilic amphipathic properties, and the skin barrier is damaged. On the other hand, keratinocytes form a stratum corneum while producing intercellular lipids such as natural moisturizing factors and ceramides, thereby enabling the stratum corneum to function as a skin barrier with firmness, elasticity of elasticity and moisturization.
본 명세서에 따른 조성물은 피부 세포 생장을 촉진시켜 준다. 또한 본 명세서에 따른 조성물은 천연보습인자 및 피부장벽 구성성분인 세라마이드의 생성량을 증가시켜 피부 보습 및 피부 탄력의 정도를 증진시켜 줌으로써, 피부 보습, 피부결 개선, 피부 재생, 피부 장벽 강화, 피부 탄력 강화에 우수한 효능을 제공한다. The composition according to the present invention promotes skin cell growth. In addition, the composition according to the present invention can increase the amount of ceramide produced, which is a natural moisturizing factor and a skin barrier component, to enhance skin moisturization and skin elasticity, thereby improving skin moisturizing, skin texture improvement, skin regeneration, Provides excellent efficacy in fortification.
상기 '피부결 개선'은 노화, 스트레스 등의 내적 또는 외적 영향으로 피부 표면이 거칠어지는 것을 억제 또는 저해함으로써 피부 표면을 매끄럽고 부드럽게 하는 것을 의미할 수 있다.The 'skin texture improvement' may mean to smooth and smooth the skin surface by inhibiting or inhibiting roughness of the skin surface due to internal or external influences such as aging and stress.
상기 '피부 재생'은 피부 세포 생장이 촉진되어 손상된 피부가 복구되거나 손상된 피부의 기능이 회복되는 것을 말하며, 상기 피부는 표피, 진피, 피하조직 (피하지방)을 의미할 수 있다.The 'skin regeneration' refers to the recovery of damaged skin or the repair of damaged skin by promoting skin cell growth, and the skin may mean epidermis, dermis, subcutaneous tissue (subcutaneous fat).
예시적인 일 구현예에서, 상기 균주는 서열번호 1의 염기서열을 포함하는 16S rDNA를 갖는 것일 수 있다.In an exemplary embodiment, the strain may be one having 16S rDNA comprising the nucleotide sequence of SEQ ID NO: 1.
예시적인 일 구현예에서, 상기 균주는 세라마이드 합성 촉진 기능을 가지는 것일 수 있다.In an exemplary embodiment, the strain may have a ceramide synthesis promoting function.
예시적인 일 구현예에서, 상기 균주는 피부 재생, 피부결 개선, 피부 보습, 피부 탄력 강화 및 피부 장벽 강화로 이루어진 군에서 선택되는 1 이상의 피부 상태 개선 기능을 가지는 것일 수 있다.In an exemplary embodiment, the strain may be one having at least one skin condition improvement function selected from the group consisting of skin regeneration, skin texture improvement, skin moisturization, skin elasticity enhancement, and skin barrier enhancement.
다른 측면에서, 본 명세서에 개시된 기술은 상기 균주를 발효 균주로 이용한 발효물 또는 이의 추출물을 제공한다.In another aspect, the technique disclosed in this specification provides a fermentation product or extract thereof using the strain as a fermentation strain.
다른 측면에서, 본 명세서에 개시된 기술은 상기 균주를 발효 균주로 이용한 발효물 또는 이의 추출물을 유효성분으로 포함하는 피부 상태 개선용 조성물을 제공한다.In another aspect, the present invention provides a composition for improving skin condition comprising, as an active ingredient, a fermentation product obtained by using the strain as a fermentation strain or an extract thereof.
다른 측면에서, 본 명세서에 개시된 기술은 상기 균주를 발효 균주로 사용하여 발효 식품을 제조하는 단계를 포함하는 발효 식품의 제조방법을 제공한다.In another aspect, the technique disclosed herein provides a method for producing a fermented food comprising the step of producing a fermented food using the strain as a fermentation strain.
예시적인 일 구현예에서, 상기 조성물은 화장료 조성물일 수 있다.In an exemplary embodiment, the composition may be a cosmetic composition.
상기 화장료 조성물에는 유효성분 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한 (制汗)제, 정제수 등을 들 수 있다.The cosmetic composition may further contain, in addition to the active ingredient, a functional additive and a component included in a general cosmetic composition. The functional additives may include water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts. Examples of the other ingredients that can be included in the composition include humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbents, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, Accelerators, coolants, antiperspirants, purified water, and the like.
상기 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 분말, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 샴푸, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The formulation of the cosmetic composition is not particularly limited and may be appropriately selected according to the purpose. For example, powder, skin lotion, skin softener, skin toner, astringent, lotion, milky lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, shampoo , A soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser. However, the present invention is not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속염, 지방산 헤미에스테르염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, have.
예시적인 일 구현예에 따르면, 상기 조성물은 약학 조성물인 것일 수 있다.According to one exemplary embodiment, the composition may be a pharmaceutical composition.
상기 약학 조성물은 유효성분 이외에 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다.The pharmaceutical composition may further contain, in addition to the active ingredient, a preservative, a stabilizer, a wetting agent or an emulsifying accelerator, a pharmaceutical adjuvant such as a salt and / or a buffer for controlling osmotic pressure, and other therapeutically useful substances, And can be formulated into various oral or parenteral dosage forms accordingly.
상기 경구 투여제는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 분제, 산제, 세립제, 과립제, 펠렛제 등이 있으며, 이들 제형은 유효성분 이외에 계면 활성제, 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로오스 및 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유할 수 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카복시메틸셀룰로오스 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제, 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, powders, powders, granules, granules and pellets, , Diluents (such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (such as silica, talc, stearic acid and magnesium or calcium salts thereof and polyethylene glycols) . The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.
또한, 상기 비경구 투여 형태로는 경피 투여형 제형일 수 있으며, 예를 들어 주사제, 점적제, 연고, 로션, 겔, 크림, 스프레이, 현탁제, 유제, 좌제(坐劑), 패취 등의 제형일 수 있으나, 이에 제한되는 것은 아니다.In addition, the parenteral administration forms may be transdermal dosage forms, and may be formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, But is not limited thereto.
상기 유효성분의 투여량 결정은 통상의 기술자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일 측면에서 상기 조성물 1 ㎍/kg 내지 200 mg/kg, 다른 일 측면에서 50 ㎍/kg 내지 50 mg/kg을 1일 1 내지 3회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.The dosage of the active ingredient is within the level of ordinary skill in the art and the daily dose of the drug depends on various factors such as the degree of progress of the subject to be administered, the age of onset, age, health condition, The composition may be administered in an amount of 1 / / kg to 200 mg / kg in one aspect, and 50 / / kg to 50 mg / kg in another aspect, divided into 1 to 3 times a day, Are not intended to limit the scope of the invention in any way.
상기 약학 조성물은 피부 외용제일 수 있으며, 상기 피부 외용제는 피부 외부에서 도포되는 어떠한 것이라도 포함될 수 있는 총칭으로서 다양한 제형의 의약품이 여기에 포함될 수 있다.The pharmaceutical composition may be an external preparation for skin, and the external preparation for skin may include any substance applied outside the skin, and may include various formulations of medicines.
예시적인 일 구현예에 따르면, 상기 조성물은 식품 조성물인 것일 수 있다.According to one exemplary embodiment, the composition may be a food composition.
상기 식품 조성물은 액상 또는 고체 상태의 제형일 수 있고, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용될 수 있다. 각 제형의 식품 조성물은 유효성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The food composition may be in a liquid or solid form and may be in the form of, for example, various foods, beverages, gums, tea, vitamin complexes, health supplements and the like and may be in the form of powders, granules, tablets, capsules or beverages . The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
본 명세서에 개시된 유효성분 외에 함유할 수 있는 액체 성분에는 특별한 제한점이 없으며, 통상의 음료와 같이 여러가지 향미제 또는 천연 탄수화물 등을 추가성분으로 포함할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 포도당, 과당 등의 디사카라이드, 말토스, 슈크로스 등의 폴리사카라이드, 덱스트린, 시클로덱스트린 등의 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올 등이 있다. 상기의 향미제로는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(예를 들어 사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 명세서에 개시된 조성물 100 ml 당 일반적으로 약 1 내지 20 g, 일 측면에서 약 5 내지 12 g일 수 있다.There are no particular limitations on the liquid components that can be contained in addition to the active ingredients disclosed in this specification, and may include various flavoring agents or natural carbohydrates such as ordinary beverages as additional ingredients. Examples of the natural carbohydrate include common saccharides such as disaccharides such as monosaccharide, glucose and fructose, polysaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol . The above flavoring agents can be advantageously used as natural flavorings (tau martin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (for example, saccharin, aspartame etc.) The ratio of the natural carbohydrate may be generally about 1 to 20 g, and in one aspect about 5 to 12 g per 100 ml of the composition disclosed herein.
상기 식품 조성물은 일 측면에서 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그 염, 알긴산 및 그 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 다른 측면에서 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 상기 성분들은 독립적으로 또는 조합하여 사용될 수 있다. 상기 첨가제의 비율은 다양할 수 있으나, 본 명세서에 개시된 조성물 100 중량부 당 0.001 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In one aspect, the food composition may include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate, etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. On the other hand, flesh for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination. The proportion of the additive may vary, but is generally selected in the range of from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
실시예Example 1. 균주의 분리 및 동정 1. Isolation and Identification of Strain
재래주 (在來酒) 발효 과정에서 락토바실러스 크러스토룸 (Lactobacillus crustorum) 균주를 하기와 같이 분리 및 동정하였다. Lactobacillus crustorum strain was isolated and identified as follows in the fermentation process of native liquor.
조를 발효하여 제주도 전통 재래주인 강술을 만들었다. 구체적으로, 조를 흐르는 물에 씻고 열풍건조 (60℃, 1시간 이상)를 통해 말리고 갈아서 가루로 만들었다. 조 가루를 익반죽하여 5~6 cm 정도의 떡 형태를 만들고 중탕하여 익혔다. 조로 만든 떡에 누룩을 1/4 중량으로 섞어 넣어주고 발효 용기에 옮긴 후 17-20℃에서 2-3개월 발효시켰다. 락토바실러스 크러스토룸 (Lactobacillus crustorum)은 발효 시작 후 1달 사이에 채집한 발효물에서 분리하였다. Joe was made into a traditional traditional Korean pottery in Jeju Island. Specifically, the bath was washed with running water and dried and hot-air dried (at 60 DEG C for 1 hour or more) to obtain a powder. I cooked the rice flour and made a rice cake shape of about 5 ~ 6 cm and cooked it with the bath. The koji rice cake was mixed with 1/4-weight of yeast, transferred to a fermentation vessel, and fermented at 17-20 ° C for 2-3 months. Lactobacillus crustorum was isolated from the fermented material collected within one month after the start of fermentation.
강술 발효물을 생리식염수 (0.85% NaCl)를 이용하여 10배, 100배의 비율로 희석한 후 유산균 분리 배지인 BCP 한천 배지 (plate count agar with bromcresol purple)에 적정량 분주하여 30-37℃에서 3일간 배양하고, 주변이 노란색으로 변하는 집락 (colony)를 취하여 MRS agar에서 2회에서 최대 4회까지 계대배양하여 단일 균주를 최종 분리하였다.The fermented product was diluted 10 times and 100 times with physiological saline (0.85% NaCl) at a ratio of 100: 1, and then added to the plate count agar with bromocresol purple. After culturing for 1 day, a colony transformed into a yellow color was taken and cultured in MRS agar from 2 to 4 times to finally isolate a single strain.
분리된 균주의 동정은 27F (5'-AGAGTTTGATCMTGGCTCAG-3', 서열번호 2)와 1492R (5'-TACGGYTACCTTGTTACGACTT-3', 서열번호 3) primer를 사용하여 16S rRNA 염기서열분석을 통하여 실시하였다. 분석된 염기서열을 Gene Bank에서 검색한 결과, 분리된 균주는 Lactobacillus crustorum strain LMG 23700과 99%의 유사성을 갖는 것을 최종 확인하여 이를 Lactobacillus crustorum JTA로 명명하고 상기 균주를 2017년 06월 27일자로 기탁기관인 한국미생물보존센터에 기탁하고 기탁번호 KCCM12048P를 부여받았다.The isolated strains were identified by 16S rRNA sequencing using 27F (5'-AGAGTTTGATCMTGGCTCAG-3 ', SEQ ID NO: 2) and 1492R (5'-TACGGYTACCTTGTTACGACTT-3', SEQ ID NO: 3) primers. The nucleotide sequence was analyzed by Gene Bank, and it was confirmed that the isolated strain had 99% similarity with Lactobacillus crustorum strain LMG 23700 and named it Lactobacillus crustorum JTA. The strain was deposited on Jun. 27, 2017 Deposited with the Korean Society for Microbiological Conservation and received the deposit number KCCM 12048P.
실시예 2. 락토바실러스 크러스토룸 (Example 2. Lactobacillus crustoleum ( Lactobacillus crustorumLactobacillus crustorum ) 균주의 배양물 및 추출물 제조) Cultures and Extracts of Strain
상기 실시예 1에서 동정된 락토바실러스 크러스토룸 JTA 균주를 MRS 배지 (MRS Broth)에서 37℃, 24시간 동안 정치배양하였다. 액체 배지 내 균 농도가 5 × 108 ~ 1 × 109 CFU/mL가 되었을 때, 4℃에서 4000 rpm의 원심 분리를 통하여 영양세포를 분리하고 상층액을 0.45 μm filter로 여과하여 배양액을 획득하였다. The Lactobacillus crustum JTA strain identified in Example 1 was cultured in MRS broth (MRS Broth) at 37 DEG C for 24 hours. When the bacterial concentration in the liquid medium reached 5 × 10 8 to 1 × 10 9 CFU / mL, the nutrient cells were separated by centrifugation at 4000 rpm at 4 ° C. and the supernatant was filtered with a 0.45 μm filter to obtain a culture solution .
또한, 남은 균체를 PBS (phosphate buffered saline)로 세척한 후 5 × 108 ~ 1 × 109 CFU/mL의 농도로 재분산 (resuspension)시키고 100℃에서 10분간 가열하여 가열 용출물을 제조하였다.The remaining cells were washed with PBS (phosphate buffered saline), resuspended at a concentration of 5 × 10 8 to 1 × 10 9 CFU / mL, and heated at 100 ° C. for 10 minutes to prepare a heated eluate.
실시예 3. 락토바실러스 크러스토룸 (Example 3. Lactobacillus crustoleum ( Lactobacillus crustorumLactobacillus crustorum ) 균주의 피부 세포 생장 촉진 효과 확인) Promoting the growth of skin cells
락토바실러스 크러스토룸 균주가 피부 세포 생장에 미치는 영향을 하기와 같이 실험하였다.The effect of Lactobacillus crustoleum strain on skin cell growth was examined as follows.
각질형성세포인 HaCaT을 5×103 cells/well의 농도로 96 well plate에 접종하고 1일 동안 5% CO2, 37℃ 조건에서 배양하여 안정화시킨 후 실험에 사용하였다. 각질형성세포의 배지를 혈청 배제 배지 (serum-free 배지)로 치환해 주고 상기 실시예 2에서 제조한 락토바실러스 크러스토룸의 배양액을 농도별로 처리하였다. 무처리군으로는 동량의 PBS (phosphate buffered saline)를 첨가하여 비교하였다. 실험은 농도별로 3회 반복하여 수행하였다. 24시간 후 세포의 증식 정도를 MTT assay를 이용하여 측정하였다.HaCaT, a keratinocyte, was inoculated into a 96-well plate at a concentration of 5 × 10 3 cells / well and incubated at 5% CO 2 and 37 ° C for 1 day. The medium of keratinocytes was replaced with serum-free medium and the culture of Lactobacillus crustorum prepared in Example 2 was treated by concentration. The same amount of PBS (phosphate buffered saline) was added to the untreated group. The experiment was repeated three times for each concentration. After 24 hours, cell proliferation was measured by MTT assay.
혈청 배제 배지 (serum-free media)로 피부 세포의 증식 속도를 늦추고 락토바실러스 크러스토룸의 배양액을 처리한 결과, 피부 세포의 증식이 촉진되어 강술에서 분리한 락토바실러스 크러스토룸의 배양액은 피부 세포 생장을 촉진시키는 효과가 있음을 확인하였다 (도 2 참조).As a result of slowing the proliferation rate of the skin cells with serum-free media and treating the culture medium of Lactobacillus crustorum, the growth of the skin cells was promoted and the culture medium of Lactobacillus crustorum isolated from the culture was added to the skin cells (See FIG. 2).
실시예 4. 락토바실러스 크러스토룸 (Example 4. Lactobacillus crustoleum ( Lactobacillus crustorumLactobacillus crustorum ) 균주의 세라마이드 생성효소 활성 촉진 및 세라마이드 생성 증진 효과 확인) Promoting activity of ceramide-producing enzyme and confirming the effect of promoting ceramide generation
락토바실러스 크러스토룸 균주가 세라마이드 생성효소의 활성 및 세라마이드의 생성량에 미치는 영향을 하기와 같이 실험하였다.The effect of Lactobacillus crustum strain on the activity of ceramide-producing enzyme and the amount of ceramide produced was examined as follows.
각질형성세포인 HaCaT을 2×105 cells/mL의 농도로 준비하여 6 well plate에 3 mL씩 접종하고 1일 동안 5% CO2, 37℃ 조건에서 배양하여 안정화시킨 후 실험에 사용하였다. 각질형성세포의 배지에 상기 실시예 2에서 제조한 락토바실러스 크러스토룸의 배양액을 농도별로 처리하고 무처리군에는 동량의 PBS (phosphate buffered saline)를 첨가하여 비교하였다. 실험은 농도별로 3회 반복하여 수행하였다. HaCaT, a keratinocyte, was prepared at a concentration of 2 × 10 5 cells / mL, and 3 mL of each of the cells was inoculated into a 6-well plate. The cells were incubated for 1 day at 5% CO 2 and 37 ° C. for stabilization. The culture of Lactobacillus crustaceum prepared in Example 2 was treated at different concentrations on the medium of keratinocytes and the same amount of PBS (phosphate buffered saline) was added to the untreated group. The experiment was repeated three times for each concentration.
24시간 후 각질형성세포의 배지를 제거하고 세포를 3 mL의 PBS로 2회 헹구어 배지를 완전히 제거하였다. 각질형성세포에 lysis buffer를 well 당 300 μL씩 처리하여 세포와 그 용출물을 수거하고 원심분리하여 용출물만을 수거하였다. 각 well의 용출물의 단백질 양을 보정하여 동일하게 맞추고 acidic sphingomyelinase assay kit (abcam, #ab190554)를 이용하여 세라마이드 생성효소의 활성을 측정하였다. 그 결과, 강술에서 분리한 락토바실러스 크러스토룸의 배양액을 피부 세포에 처리한 결과 세라마이드 생성효소의 활성을 증가시킴을 확인하였다 (도 3 참조). After 24 hours, the medium of keratinocytes was removed and the cells were rinsed twice with 3 mL of PBS to completely remove the medium. The keratinocytes were treated with 300 μL of lysis buffer per well and the cells and their eluates were collected and centrifuged to collect only the eluate. The amount of protein in each eluate was corrected and the activity of ceramide production enzyme was measured using an acidic sphingomyelinase assay kit (abcam, # ab190554). As a result, it was confirmed that treatment of the culture solution of Lactobacillus crustaceum isolated from the culture with skin cells increased the activity of ceramide-producing enzyme (see FIG. 3).
또한, 상기의 방법과 동일하게 각질형성세포에 상기 실시예 2에서 제조한 락토바실러스 크러스토룸의 배양액을 처리하고 각질형성세포의 용출물을 준비하였다. 원심분리한 용출물의 단백질 양을 보정하여 동일하게 맞추고 에탄올을 이용하여 지질을 추출하였다. 세라마이드의 양은 지질 추출물을 ο-프탈알데히드 (ο-phthalaldehyde)로 유도체화한 후 HPLC로 측정하였다. 그 결과, 무처리군의 세라마이드 양을 기준으로, 락토바실러스 크러스토룸의 배양액을 처리한 각질형성세포는 세라마이드 생성량을 증가시키는 것을 확인하였다 (도 4 참조).In addition, in the same manner as the above-mentioned method, the keratinocyte was treated with the culture of the Lactobacillus crustaceum prepared in Example 2, and eluates of keratinocytes were prepared. The protein amount of the centrifuged eluate was corrected and the lipids were extracted using ethanol. The amount of ceramide was determined by HPLC after derivatization of the lipid extract with ο-phthalaldehyde. As a result, it was confirmed that the keratinocytes treated with the culture medium of Lactobacillus crestorum on the basis of the amount of ceramide in the untreated group increased the amount of ceramide produced (see FIG. 4).
본 명세서의 일 측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of compositions according to one aspect of the present disclosure are described below, but are applicable to various other formulations, which are not intended to be limiting, but rather to illustrate only specifically.
제형예 1. 유연화장수Formulation Example 1. Softening Time
상기 실시예 2의 락토바실러스 크러스토룸 배양액 0.01 중량%, 글리세린 3 중량%, 부틸렌 글리콜 2 중량%, 프로필렌 글리콜 2 중량%, 카복시비닐폴리머 0.1 중량%, 에탄올 10 중량%, 트리에탄올아민 0.1 중량% 및 잔량의 방부제, 미량 색소, 미량 향료 및 미량 정제수를 혼합하여 통상의 유연화장수 제조방법에 따라 제조하였다.The culture broth of Lactobacillus crustum cultures of Example 2, containing 3 wt% of glycerin, 2 wt% of butylene glycol, 2 wt% of propylene glycol, 0.1 wt% of carboxyvinyl polymer, 10 wt% of ethanol, 0.1 wt% of triethanolamine, And minor amounts of preservatives, trace pigments, trace flavors and trace amounts of purified water were mixed and prepared according to a conventional method for preparing softened water.
제형예 2. 영양화장수Formulation Example 2. Nourishing Lotion
상기 실시예 2의 락토바실러스 크러스토룸 배양액 0.01 중량%, 밀납 4 중량%, 폴리소르베이트 60 1.5 중량%, 소르비탄세스퀴올레이트 0.5 중량%, 유동파라핀 5 중량%, 스쿠알란 5 중량%, 카프릴릭/카프릭 트리글리세라이드 5 중량%, 글리세린 3 중량%, 부틸렌 글리콜 3 중량%, 프로필렌 글리콜 3 중량%, 카복시비닐폴리머 0.1 중량%, 트리에탄올아민 0.2 중량%, 잔량의 방부제, 미량 색소, 미량 향료 및 미량 정제수를 혼합하여 통상의 영양화장수 제조방법에 따라 제조하였다.The culture broth of Example 2, containing 0.01 wt% of Lactobacillus crustum culture, 4 wt% of wax, 1.5 wt% of
제형예 3. 영양크림Formulation Example 3. Nourishing cream
상기 실시예 2의 락토바실러스 크러스토룸 배양액 0.01 중량%, 밀납 10 중량%, 폴리소르베이트 60 1.5 중량%, 소르비탄세스퀴올레이트 0.5 중량%, 유동파라핀 10 중량%, 스쿠알란 5 중량%, 카프릴릭/카프릭 트리글리세라이드 5 중량%, 글리세린 5 중량%, 부틸렌 글리콜 3 중량%, 프로필렌 글리콜 3 중량%, 트리에탄올아민 0.2 중량% 및 잔량의 방부제, 미량 색소, 미량 향료 및 미량 정제수를 혼합하여 통상의 영양크림 제조방법에 따라 제조하였다.The culture broth of Lactobacillus crustum cultures of Example 2, containing 10 wt% of wax, 10 wt% of
제형예 4. 팩Formulation Example 4. Pack
상기 실시예 2의 락토바실러스 크러스토룸 배양액 0.01 중량%, 폴리비닐알콜 13 중량%, 소듐카복시메틸셀룰로스 0.2 중량%, 알란토인 0.1 중량%, 에탄올 5 중량%, 노닐페닐에테르 0.3 중량% 및 잔량의 방부제, 미량 색소, 미량 향료 및 미량 정제수를 혼합하여 통상의 팩 제조방법에 따라 제조하였다.The culture broth of Lactobacillus crustum cultured in Example 2, containing 0.1% by weight of polyvinyl alcohol, 0.2% by weight of sodium carboxymethyl cellulose, 0.1% by weight of allantoin, 5% by weight of ethanol, 0.3% by weight of nonylphenyl ether, , A trace pigment, a trace amount of flavor, and a trace amount of purified water were mixed and prepared according to a conventional pack preparation method.
이상, 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
<110> AMOREPACIFIC CORPORATION
<120> COMPOSITION COMPRISING CULTURE OR ITS EXTRACT OF LACTOBACILLUS
CRUSTORUM
<130> 17P426/IND
<160> 3
<170> KoPatentIn 3.0
<210> 1
<211> 883
<212> DNA
<213> Unknown
<220>
<223> Lactobacillus crustorum JTA
<400> 1
cccagcggag tgcttaatgc gttagctgca gcactgaagg gcggaaaccc tccaacactt 60
agcactcatc gtttacggca tggactacca gggtatctaa tcctgtttgc tacccatgct 120
ttcgaatctc agcgtcagtt acagaccaga aagccgcctt cgccactggt gttcttccat 180
atatctacgc attccaccgc tacacatgga gttccacttt cctcttctgc actcaagttt 240
accagttttc gaagcacttc ctcggttgag ccgagggctt tcacttcaaa cttaataaac 300
cgcctacatt ctctttacgc ccaataaatc cggacaacgc ttgccaccta cgtattaccg 360
cggctgctgg cacgtagtta gccgtggctt tctggttgaa taccgtcagt acgtgaacag 420
ttactctcac gcatgttctt cttcaacaac agagttttac gatccgaaaa ccttcttcac 480
tcacgcggca ttgctccatc aggctttcgc ccattgtgga agattcccta ctgctgcctc 540
ccgtaggagt ttgggccgtg tctcagtccc aatgtggccg attaccctct caggtcggct 600
acgtatcatt gccttggtga gctattacct caccaactag ctaatacgcc gcgggtccat 660
ccaaaagcga tagcagagcc atctttcaag ctacgatcat gagaaagtag ttgttatgcg 720
gtattagcac ctgtttccag atgttatccc ccacttttgg gcaggttacc cacgtgttac 780
tcacccgtcc gccactcacc aaggtctgaa tcatgaagca agcttcaatc ttcaggatgg 840
ttcgttcgac ttgcatgtat taggcatgcc gccagcgttc gtc 883
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> 27F primer
<400> 2
agagtttgat cmtggctcag 20
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> 1492R primer
<400> 3
tacggytacc ttgttacgac tt 22
<110> AMOREPACIFIC CORPORATION
<120> COMPOSITION COMPRISING CULTURE OR ITS EXTRACT OF LACTOBACILLUS
CRUSTORUM
<130> 17P426 / IND
<160> 3
<170> KoPatentin 3.0
<210> 1
<211> 883
<212> DNA
<213> Unknown
<220>
<223> Lactobacillus crustorum JTA
<400> 1
cccagcggag tgcttaatgc gttagctgca gcactgaagg gcggaaaccc tccaacactt 60
agcactcatc gtttacggca tggactacca gggtatctaa tcctgtttgc tacccatgct 120
ttcgaatctc agcgtcagtt acagaccaga aagccgcctt cgccactggt gttcttccat 180
atatctacgc attccaccgc tacacatgga gttccacttt cctcttctgc actcaagttt 240
accagttttc gaagcacttc ctcggttgag ccgagggctt tcacttcaaa cttaataaac 300
cgcctacatt ctctttacgc ccaataaatc cggacaacgc ttgccaccta cgtattaccg 360
cggctgctgg cacgtagtta gccgtggctt tctggttgaa taccgtcagt acgtgaacag 420
ttactctcac gcatgttctt cttcaacaac agagttttac gatccgaaaa ccttcttcac 480
tcacgcggca ttgctccatc aggctttcgc ccattgtgga agattcccta ctgctgcctc 540
ccgtaggagt ttgggccgtg tctcagtccc aatgtggccg attaccctct caggtcggct 600
acgtatcatt gccttggtga gctattacct caccaactag ctaatacgcc gcgggtccat 660
ccaaaagcga tagcagagcc atctttcaag ctacgatcat gagaaagtag ttgttatgcg 720
gtattagcac ctgtttccag atgttatccc ccacttttgg gcaggttacc cacgtgttac 780
tcacccgtcc gccactcacc aaggtctgaa tcatgaagca agcttcaatc ttcaggatgg 840
ttcgttcgac ttgcatgtat taggcatgcc gccagcgttc gtc 883
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> 27F primer
<400> 2
Claims (14)
Lactobacillus crustorum strain; Disruption thereof; A culture thereof; Or an extract of said strain, lysate or culture, as an active ingredient.
상기 균주는 기탁번호가 KCCM12048P인 락토바실러스 크러스토룸 JTA인, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the strain is Lactobacillus crestorum JTA with an accession number KCCM12048P.
상기 균주는 서열번호 1의 염기서열을 포함하는 16S rDNA를 갖는 것인, 피부 상태 개선용 조성물.
3. The method of claim 2,
Wherein the strain has 16S rDNA comprising the nucleotide sequence of SEQ ID NO: 1.
상기 추출물은 열수 추출물인, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the extract is a hot-water extract.
상기 유효성분은 조성물 전체 중량을 기준으로 0.001 내지 30 중량%로 포함되는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the active ingredient is contained in an amount of 0.001 to 30% by weight based on the total weight of the composition.
상기 조성물은 피부 재생 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a skin regeneration purpose.
상기 조성물은 피부결 개선 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a skin tone improving composition.
상기 조성물은 피부 보습 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a skin moisturizing application.
상기 조성물은 피부 탄력 강화 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a skin elasticity-enhancing use.
상기 조성물은 피부 장벽 강화 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a skin barrier enhancing use.
상기 조성물은 세라마이드 합성 촉진 용도를 갖는, 피부 상태 개선용 조성물.
The method according to claim 1,
Wherein the composition has a ceramide synthesis promoting use.
Lactobacillus crustorum JTA strain with a deposit number of KCCM 12048P .
상기 균주는 세라마이드 합성 촉진 기능을 가지는 것인, 균주.
13. The method of claim 12,
Wherein said strain has a ceramide synthesis promoting function.
상기 균주는 피부 재생, 피부결 개선, 피부 보습, 피부 탄력 강화 및 피부 장벽 강화로 이루어진 군에서 선택되는 1 이상의 피부 상태 개선 기능을 가지는 것인, 균주.13. The method of claim 12,
Wherein the strain has at least one skin condition improving function selected from the group consisting of skin regeneration, skin texture improvement, skin moisturization, skin elasticity enhancement and skin barrier enhancement.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170125293A KR102311725B1 (en) | 2017-09-27 | 2017-09-27 | Composition comprising culture or its extract of lactobacillus crustorum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170125293A KR102311725B1 (en) | 2017-09-27 | 2017-09-27 | Composition comprising culture or its extract of lactobacillus crustorum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190036272A true KR20190036272A (en) | 2019-04-04 |
| KR102311725B1 KR102311725B1 (en) | 2021-10-13 |
Family
ID=66105577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170125293A KR102311725B1 (en) | 2017-09-27 | 2017-09-27 | Composition comprising culture or its extract of lactobacillus crustorum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102311725B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102349372B1 (en) * | 2021-04-21 | 2022-01-11 | 일동바이오사이언스(주) | Cosmetic composition for promoting the ceramide formation |
| KR20230041509A (en) * | 2021-09-17 | 2023-03-24 | 코스맥스 주식회사 | Bacillus infantis HB2 strain and its use for improving skin conditions |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000057210A (en) * | 1996-11-22 | 2000-09-15 | 드 시모네 클라우디오 | Sphingomyelinase compositions and use thereof |
| KR20140008684A (en) * | 2012-07-11 | 2014-01-22 | (주)미애부생명과학 | Novel strain of lactobacillus fermentum spp., cosmetic composition using the same and preparation method thereof |
| KR20140089805A (en) * | 2013-01-07 | 2014-07-16 | (주)미애부생명과학 | Cosmetic Composition Having Culture Fluid of Lactobacillus sp. and Stem cells |
| KR20150140833A (en) * | 2013-04-15 | 2015-12-16 | 그린떼끄 | Cosmetic and pharmaceutical applications of lactobacillus pentosus |
| KR101719223B1 (en) | 2014-10-28 | 2017-03-23 | 주식회사 코리아나화장품 | Cosmetic composition for promoting ceramide biosynthesis containing Panax ginseng, honey, and propolis fermented by kimchi lactic acid bacteria |
-
2017
- 2017-09-27 KR KR1020170125293A patent/KR102311725B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000057210A (en) * | 1996-11-22 | 2000-09-15 | 드 시모네 클라우디오 | Sphingomyelinase compositions and use thereof |
| KR20140008684A (en) * | 2012-07-11 | 2014-01-22 | (주)미애부생명과학 | Novel strain of lactobacillus fermentum spp., cosmetic composition using the same and preparation method thereof |
| KR20140089805A (en) * | 2013-01-07 | 2014-07-16 | (주)미애부생명과학 | Cosmetic Composition Having Culture Fluid of Lactobacillus sp. and Stem cells |
| KR20150140833A (en) * | 2013-04-15 | 2015-12-16 | 그린떼끄 | Cosmetic and pharmaceutical applications of lactobacillus pentosus |
| KR101719223B1 (en) | 2014-10-28 | 2017-03-23 | 주식회사 코리아나화장품 | Cosmetic composition for promoting ceramide biosynthesis containing Panax ginseng, honey, and propolis fermented by kimchi lactic acid bacteria |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102349372B1 (en) * | 2021-04-21 | 2022-01-11 | 일동바이오사이언스(주) | Cosmetic composition for promoting the ceramide formation |
| WO2022225095A1 (en) * | 2021-04-21 | 2022-10-27 | 일동바이오사이언스(주) | Cosmetic composition for improving ceramide formation |
| KR20230041509A (en) * | 2021-09-17 | 2023-03-24 | 코스맥스 주식회사 | Bacillus infantis HB2 strain and its use for improving skin conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102311725B1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5791009B2 (en) | Lactic acid bacteria and food or drink using them | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR102287584B1 (en) | Composition comprising Lactobacillus sakei derived from Lonicera japonica Thunb. or cultured products thereof as a active ingredient | |
| KR20190079514A (en) | Cosmetic composition for skin moisturizing comprising fermented aloe as effective component | |
| KR101409764B1 (en) | Comprising lactic acid fermentation product of Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR20190063549A (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
| KR20210066996A (en) | Antibacterial or skin moisturizing composition comprising extracellular vesicles derived from lactic acid bacteria | |
| KR102311725B1 (en) | Composition comprising culture or its extract of lactobacillus crustorum | |
| KR101578581B1 (en) | A novel bacterium Chryseobacterium sp. THG-C4-1, and a method for producing gypenoside 17 using the same | |
| KR20100013357A (en) | Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment | |
| KR102263454B1 (en) | Skin derived novel lactic acid bacteria having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
| KR20220077991A (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
| KR101796955B1 (en) | Cosmetic Composition Comprising the Extract of Mixed Fermentation with Sanguisorba Officinalis and Piper Longum Linn. showing Skin Anti-Aging and Whitening Effect, a preparation method thereof | |
| KR102119524B1 (en) | Cosmetic composition comprising the extract of fermented Sprout leaf/stem ginseng for skin anti-wrinkle effect and producing method thereof | |
| KR20210155989A (en) | Composition Comprising Lactobacillus sakei, Culture Fluid, or Culture Fluid Extract thereof with Anti-Wrinkling and Elasticity, Skin Cell Regeneration, and Skin Barrier Property as Active Ingredient | |
| KR102485257B1 (en) | Composition comprising lactic acid bacteria derived from camellia japonica for caring damages of skin cells by microdust | |
| US20240207169A1 (en) | Composition for improving skin wrinkle, moisturizing, strengthening skin barrier, and promoting skin regeneration, comprising mixed lactic acid bacteria as active ingredient | |
| KR102361015B1 (en) | Use of Sphingomonas olei to improve skin condition | |
| KR101908976B1 (en) | A cosmetic composition containing lactobacillus-fermented extract for improving atopic dermatitis | |
| KR102389749B1 (en) | Skin derived novel Lactobacillus fermentum subsp. shebah-101 strain having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
| KR102389753B1 (en) | Skin derived novel Lactobacillus plantarum subsp. shebah-202 strain having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
| KR102610934B1 (en) | Composition for hair or scalp comprising lysate of Lactobacillus sakei | |
| KR102036530B1 (en) | Cosmetic composition comprising probiotics | |
| KR102395985B1 (en) | Anti-aging composition comprising culture or its extract of microorganism of serratia genus | |
| KR102663013B1 (en) | Composition for Skin Moisturizing, Skin Barrier, Elasticity and Improving Skin Itching Comprising Lactobacillus Complex Strain as Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |